al-Sarraf R, Mauldin G N, Patnaik A K, Meleo K A
Donaldson-Arwood Cancer Clinic, Animal Medical Center, New York, NY, USA.
J Vet Intern Med. 1996 Nov-Dec;10(6):376-8. doi: 10.1111/j.1939-1676.1996.tb02084.x.
Surgery, chemotherapy, and irradiation have been used singly or in combination to treat dogs with cutaneous grade-2 mast cell tumors (MCT). However, optimal treatment has not been established. At The Animal Medical Center, 32 dogs with grade 2, stage 0 MCT received cobalt radiation treatment to a dose of 54 Gy; 94% had a disease-free interval of 1 year. The 2-,3-,4-, and 5-year disease-free intervals were 86%. Survival rates were 100% for 1 year and 96% for 2 to 5 years, with only 1 death caused by MCT. Primary site was not a prognostic factor for survival in this study. Minimal toxicity was observed and was limited to acute cutaneous reactions. Late-term reactions to radiation therapy were mild and considered acceptable in all cases. No deaths occurred due to treatment, and no dog was eliminated from the study because of radiation therapy toxicity. Radiation therapy appears to be an effective treatment for dogs with grade 2, stage 0 MCT.
手术、化疗和放疗已被单独或联合用于治疗患有皮肤2级肥大细胞瘤（MCT）的犬类。然而，尚未确定最佳治疗方法。在动物医疗中心，32只患有2级0期MCT的犬接受了剂量为54 Gy的钴辐射治疗；94%的犬无病间隔期为1年。2年、3年、4年和5年的无病间隔率为86%。1年生存率为100%，2至5年生存率为96%，仅1例死于MCT。在本研究中，原发部位不是生存的预后因素。观察到的毒性最小，仅限于急性皮肤反应。放疗的晚期反应轻微，在所有病例中均被认为可以接受。没有因治疗导致死亡，也没有犬因放疗毒性而退出研究。放疗似乎是治疗2级0期MCT犬的有效方法。
